TMO · 10-Q · 2026Q3 · Full report

Instrument and Bioproduction Demand

THERMO FISHER SCIENTIFIC INC. · 2026-10-30 · Importance 32 · Surprise 24

Life Sciences Solutions’ organic revenue growth in the third quarter and first nine months of 2026 was driven by bioproduction, with higher demand from pharma and biotech customers. Analytical Instruments’ organic growth was driven by electron microscopy and chromatography and mass spectrometry. The filing also cites customer demand for innovative high-end instruments as a driver of strong industrial and applied market performance.

Key facts

• In the first nine months of 2026, Thermo Fisher Scientific Inc.’s bioproduction business grew $496 million on a reported basis, driven by higher pharma and biotech demand and the 2025 filtration and separation acquisition. source
• In the first nine months of 2026, Thermo Fisher Scientific Inc.’s electron microscopy and chromatography and mass spectrometry businesses grew $123 million and $81 million, respectively, each contributing 2 percentage points of reported Analytical Instruments segment growth. source
• In the third quarter of 2026, Thermo Fisher Scientific Inc.’s bioproduction business grew $79 million on a reported basis, contributing 3 percentage points of reported Life Sciences Solutions segment growth, driven by higher pharma and biotech demand and the 2025 filtration and separation business acquisition. source
• In the third quarter of 2026, Thermo Fisher Scientific Inc.’s electron microscopy business increased $94 million and its chromatography and mass spectrometry businesses increased $18 million, contributing 5 and 1 percentage points, respectively, of reported Analytical Instruments segment growth. source
• In the third quarter of 2026, Thermo Fisher Scientific Inc.’s revenue in the industrial and applied market was very strong, driven by customer demand for innovative high-end instruments. source
• In the first nine months of 2026, Thermo Fisher Scientific Inc.’s revenues in the industrial and applied market were strong, driven by demand for innovative high-end instruments. source
• In the third quarter of 2026, Thermo Fisher Scientific Inc.’s Life Sciences Solutions organic revenue increase was primarily driven by bioproduction. source
• In the first nine months of 2026, Thermo Fisher Scientific Inc.’s Life Sciences Solutions organic revenue increase was driven by bioproduction. source